1. Report Introduction 2. Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance 2.1. Market Share Distribution of Chemotherapy Induced Neutropenia (CIN) in 2016 2.2. Market Share Distribution of Chemotherapy Induced Neutropenia (CIN) in 2028 3. Disease Background and Overview: Chemotherapy Induced Neutropenia (CIN) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Chemotherapy Induced Neutropenia (CIN) in 7MM 4.3. Total Prevalent Patient Population of Chemotherapy Induced Neutropenia (CIN) in 7MM – By Countries 5. Epidemiology of Chemotherapy Induced Neutropenia (CIN) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) 5.1.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) * 5.1.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)* 5.1.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) 5.1.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) 5.4.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)* 5.4.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)* 5.4.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) 5.4.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) 5.5.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)* 5.5.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)* 5.5.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) 5.5.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) 5.6.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)* 5.6.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)* 5.6.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) 5.6.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) 5.7.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)* 5.7.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)* 5.7.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) 5.7.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) 5.8.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)* 5.8.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)* 5.8.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) 5.8.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) 5.9.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)* 5.9.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)* 5.9.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) 5.9.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Chemotherapy Induced Neutropenia (CIN) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Chemotherapy Induced Neutropenia (CIN) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Chemotherapy Induced Neutropenia (CIN): 7MM Market Analysis 12.1. 7MM Market Size of Chemotherapy Induced Neutropenia (CIN) 12.2. 7MM Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) 12.3. 7MM Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products 13. Chemotherapy Induced Neutropenia (CIN): Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in United States 13.1.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in United States 13.1.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in Germany 13.2.1.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in Germany 13.2.1.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in France 13.2.2.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in France 13.2.2.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in Italy 13.2.3.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in Italy 13.2.3.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in Spain 13.2.4.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in Spain 13.2.4.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in United Kingdom 13.2.5.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in Japan 13.3.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in Japan 13.3.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in 7MM Table 2: Total Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Table 5: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Table 6: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Table 7: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Table 11: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Table 12: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Table 14: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Table 15: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Table 16: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Table 17: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Table 21: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Table 22: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Table 26: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Table 27: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Table 30: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Table 31: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Table 32: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Table 36: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Table 37: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Table 42:7MM- Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Table 45: United States-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Table 48: Germany-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Table 51: France-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Table 54: Italy-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Table 57: Spain-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Table 60:UK-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Table 63: Japan-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in 7MM Figure 2: Total Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Figure 6: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Figure 7: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Figure 12: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Figure 15: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Figure 16: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Figure 17: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Figure 22: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Figure 27: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Figure 31: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Figure 32: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Figure 37: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Figure 42:7MM- Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Figure 45: United States-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Figure 48: Germany-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Figure 51: France-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Figure 54: Italy-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Figure 57: Spain-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Figure 60:UK-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028) Figure 63: Japan-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)